Checkpoint inhibitors target specific molecules such as PD-1, PD-L1, and CTLA-4. By inhibiting these checkpoints, the drugs enable T cells, a type of white blood cell, to recognize and destroy cancer cells. This form of therapy is part of a broader category known as immunotherapy.
